We developed a circadian clock-related prognostic signature that could distinguish pancreatic ductal adenocarcinoma (PADA) patients with unwanted prognostic outcomes from those with desirable prognostic outcomes and be reflective of response to molecular targeted therapy. This evidence concerns the gene CLOCK and pancreatic ductal adenocarcinoma.